Stock Research Monitor: FMI, NEO, and STIM
LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on TROV sign up now at www.wallstequities.com/registration. WallStEquities.com draws investors' attention to the Medical Laboratories and Research category, which includes companies that focus on performing various tests on patients that give them information on patients' health. These firms, as a whole, tend to offer higher dividend yields than the wider healthcare sector. Lined up for review are the following equities: Foundation Medicine Inc. (NASDAQ: FMI), NeoGenomics Inc. (NASDAQ: NEO), Neuronetics Inc. (NASDAQ: STIM), and TrovaGene Inc. (NASDAQ: TROV). All you have to do is sign up today for this free limited time offer by clicking the link below.
Cambridge, Massachusetts headquartered Foundation Medicine Inc.'s shares declined slightly by 0.04%, closing Thursday's trading session at $136.75. The stock recorded a trading volume of 815,420 shares, which was above its three months average volume of 615,700 shares. The Company's shares have advanced 0.11% in the last month, 76.91% over the previous three months, and 268.10% over the past year. The stock is trading 17.18% above its 50-day moving average and 74.27% above its 200-day moving average. Additionally, shares of Foundation Medicine, which provides various molecular information products in the US, have a Relative Strength Index (RSI) of 76.95.
On July 18th, 2018, Foundation Medicine announced an agreement to settle a patent infringement lawsuit brought by Foundation Medicine against Guardant concerning US Patent No. 9,340,830. Under the terms of the settlement, the lawsuit and counterclaims, as well as challenges to the patent in inter parties review, have been dismissed. Financial terms and other specifics of the settlement were not disclosed. Get the full research report on FMI for free by clicking below at:
On Thursday, shares in Fort Myers, Florida headquartered NeoGenomics Inc. recorded a trading volume of 475,725 shares. The stock rose slightly by 0.07%, ending the day at $13.81. The Company's shares have advanced 0.29% in the past month, 43.85% in the previous three months, and 46.91% over the past year. The stock is trading above its 50-day and 200-day moving averages by 6.24% and 40.82%, respectively. Furthermore, shares of NeoGenomics, which together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the US, have an RSI of 55.24.
On July 24th, 2018, NeoGenomics reported its results for Q2 2018. Consolidated revenues for the quarter were $67.7 million, consolidated gross profit was $30.5 million, and consolidated gross margin was 45.1%. Net loss in Q2 2018 was $0.4 million, and adjusted EBITDA was $10.1 million. NEO's complimentary research coverage is a few simple steps away at:
Malvern, Pennsylvania headquartered Neuronetics Inc.'s stock finished the day flat at $25.92. A total volume of 65,988 shares was traded. Shares of the Company, which designs, develops, and markets products for patients with psychiatric disorders, are trading below their 50-day moving average by 1.33%.
On July 02nd, 2018, Neuronetics announced the closing of its IPO of 6,325,000 shares of the Company's common stock, including the exercise in full of the underwriters' option to purchase 825,000 additional shares of common stock, at a public offering price of $17.00 per share. The aggregate gross proceeds to the Company from the offering were $107.5 million, before deducting underwriting discounts and offering expenses.
On July 24th, 2018, research firm Canaccord Genuity initiated a 'Buy' rating on the Company's stock. Register for your free research report on STIM at:
Shares in San Diego, California headquartered TrovaGene Inc. ended yesterday's session 4.18% lower at $0.72. The stock recorded a trading volume of 996,457 shares, which was above its three months average volume of 686,590 shares. The Company's shares are trading 52.07% below their 50-day moving average. Moreover, shares of TrovaGene, which develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring technology in tumor genomics, have an RSI of 14.39.
On July 09th, 2018, TrovaGene provided an update on key value-creating milestones for the second half of 2018. The Company anticipates achieving Phase-1b/2 trial of PCM-075 in combination with either low-dose Cytarabine or Decitabine for the Treatment of acute myeloid leukemia. The Company also anticipates Phase-2 trial of PCM-075 in combination with Abiraterone Acetate (Zytiga®) and Prednisone for the treatment of metastatic castration-resistant prostate cancer. Wall St. Equities' downloadable research report on TROV available at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities